-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Lowers Price Target to $5.6

Benzinga·11/18/2026 16:09:31
Listen to the news
Morgan Stanley analyst Vikram Purohit maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Equal-Weight and lowers the price target from $5.9 to $5.6.